ORG Wealth Partners LLC Sells 1,122 Shares of Novo Nordisk A/S (NYSE:NVO)

ORG Wealth Partners LLC reduced its position in shares of Novo Nordisk A/S (NYSE:NVO) by 42.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,510 shares of the company’s stock after selling 1,122 shares during the period. ORG Wealth Partners LLC’s holdings in Novo Nordisk A/S were worth $130,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in NVO. Strategic Investment Solutions Inc. IL bought a new position in shares of Novo Nordisk A/S during the second quarter valued at about $25,000. Daiwa Securities Group Inc. bought a new position in shares of Novo Nordisk A/S during the third quarter valued at about $28,000. Abound Wealth Management lifted its position in shares of Novo Nordisk A/S by 257.4% during the second quarter. Abound Wealth Management now owns 218 shares of the company’s stock valued at $31,000 after purchasing an additional 157 shares in the last quarter. Capital Performance Advisors LLP bought a new position in shares of Novo Nordisk A/S during the third quarter valued at about $42,000. Finally, Carolina Wealth Advisors LLC bought a new stake in Novo Nordisk A/S in the third quarter worth about $48,000. 11.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on NVO. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BMO Capital Markets lowered their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Finally, StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Price Performance

NVO opened at $86.41 on Friday. The company has a market capitalization of $387.77 billion, a price-to-earnings ratio of 27.96, a PEG ratio of 1.37 and a beta of 0.45. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The firm has a 50-day moving average price of $100.35 and a 200-day moving average price of $119.40. Novo Nordisk A/S has a twelve month low of $81.50 and a twelve month high of $148.15.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.